Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
Hamraz Mokri (mokri@eshpm.eur.nl),
Ingelin Kvamme (kvamme@imta.eur.nl),
Linda Vries,
Matthijs Versteegh and
Pieter Baal
Additional contact information
Hamraz Mokri: Erasmus University Rotterdam
Ingelin Kvamme: Erasmus University Rotterdam
Linda Vries: Erasmus University Rotterdam
Matthijs Versteegh: Erasmus University Rotterdam
Pieter Baal: Erasmus University Rotterdam
The European Journal of Health Economics, 2023, vol. 24, issue 5, No 3, 715 pages
Abstract:
Abstract When healthcare interventions prolong life, people consume medical and non-medical goods during the years of life they gain. It has been argued that the costs for medical consumption should be included in cost-effectiveness analyses from both a healthcare and societal perspective, and the costs for non-medical consumption should additionally be included when a societal perspective is applied. Standardized estimates of these so-called future costs are available in only a few countries and the impact of inclusion of these costs is likely to differ between countries. In this paper we present and compare future costs for five European countries and estimate the impact of including these costs on the cost-effectiveness of life-prolonging interventions. As countries differ in the availability of data, we illustrate how both individual- and aggregate-level data sources can be used to construct standardized estimates of future costs. Results show a large variation in costs between countries. The medical costs for the Netherlands, Germany, and the United Kingdom are large compared to Spain and Greece. Non-medical costs are higher in Germany, Spain, and the United Kingdom than in Greece. The impact of including future costs on the ICER similarly varied between countries, ranging from €1000 to €35,000 per QALY gained. The variation between countries in impact on the ICER is largest when considering medical costs and indicate differences in both structure and level of healthcare financing in these countries. Case study analyses were performed in which we highlight the large impact of including future costs on ICER relative to willingness-to-pay thresholds.
Keywords: Economic evaluation; Future costs; Non-medical costs; Medical cost; Incremental cost-effectiveness ratio; Cost estimation (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:
Downloads: (external link)
http://link.springer.com/10.1007/s10198-022-01501-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:24:y:2023:i:5:d:10.1007_s10198-022-01501-6
Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2
DOI: 10.1007/s10198-022-01501-6
Access Statistics for this article
The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg
More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla (sonal.shukla@springer.com) and Springer Nature Abstracting and Indexing (indexing@springernature.com).